Point72 Asset Management L.P. Reduces Stock Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

Point72 Asset Management L.P. lowered its stake in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) by 83.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 91,300 shares of the company’s stock after selling 451,600 shares during the period. Point72 Asset Management L.P.’s holdings in ABIVAX Société Anonyme were worth $668,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth $36,000. Bank of America Corp DE raised its position in shares of ABIVAX Société Anonyme by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth $85,000. Guggenheim Capital LLC purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth $92,000. Finally, BNP Paribas Financial Markets raised its position in shares of ABIVAX Société Anonyme by 47.5% in the fourth quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company’s stock worth $141,000 after buying an additional 6,200 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

NASDAQ ABVX opened at $6.05 on Friday. The stock’s 50-day simple moving average is $6.39 and its two-hundred day simple moving average is $7.15. ABIVAX Société Anonyme has a twelve month low of $4.77 and a twelve month high of $14.71.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABVX. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.